Down-Regulated miR-130a/b Attenuates Rhabdomyosarcoma Proliferation .

Rhabdomyosarcoma (RMS) is one of the most common types of soft-tissue sarcomas in children, and it exhibits a low 5-years survival rate. The survival outcome has shown no significant improvements in the past 30 years miRNA profiling of RMS might therefore provide a novel insight into uncovering new molecular targets for therapy. We analyzed miRNA and RNA sequencing data from patients and the TARGET database to reveal the potential miRNA-mRNA axes and validated them in patients' samples. After the miRNA antagomirs were used to silence the target miRNAs in the cell model, qRT-PCR, western immunoblotting analysis, and proliferation assays were performed to explore the interaction between miR-130a/b and peroxisome proliferator-activated receptor gamma (PPARG) and their effects. In RMS patients, the expression of miR-130a/b was augmented, and its related gene was suppressed. Bioinformatics analysis showed that miR-130a/b targeted the gene and inhibited the proliferation of human RMS cell lines. In addition, rosiglitazone maleate activated the expression of in human RMS cell lines to suppress proliferation. miR-130a/b regulates the malignant process in RMS by targeting . Furthermore, the agonist rosiglitazone maleate attenuated the proliferation of RD cells and might therefore be of benefit to RMS patients.